期刊文献+

高分辨率溶解曲线分析miRNA-196a2基因多态性与肺癌相关性 被引量:1

High resolution melting analysis of the correlation of the miRNA-196a2 gene polymorphism and lung cancer
下载PDF
导出
摘要 目的探讨microRNA-196a2基因多态性(rs1614913)与中国人群肺癌发病相关性。方法应用高分辨率溶解曲线(high resolution melting,HRM)分析技术对32例肺癌患者、27例肺部良性肿瘤患者及84例健康个体的microRNA-196a2基因多态性进行分析,并采用聚合酶链反应-限制性片段长度多态性(PCR-restriction fragment length polymorphism,PCRRFLP)技术加以佐证。结果 micro-196a2在各组基因型分布均达到Hardy-Weinberg平衡。肺癌组C等位基因的分布频率高于对照组(P=0.0016),OR=2.592(95%CI1.424~4.716),说明C等位基因增加肺癌患病风险。结论 MicroRNA-196a2T/C(rs1614913)多态性增加肺癌的发病风险。MicroRNA-196a2基因多态性rs1614913可能是肺癌的一种有效的遗传标记物。 Objective To investigate the effect of the microRNA-1962 gene polymorphism on risk of lung cancer.MethodsThirty-two patients with lung cancer,27 patients with benign neoplasm in lung and 84 healthy controls.All subjects were genotyped for the microRNA-196a2 SNP by high resolution melting analysis,and the results were supported by PCR-restriction fragment length polymorphism method.Results The microRNA 1962 agenotype distribution among three group was in Hardyweinberg equilibrium.The frequency of the C allele in group of lung cancer was higher than that of the control group(P=0.0016).The odds ratio 2.592(95% CI 1.424~4.716)suggested an association of the C allele with increased risk of lung cancer.Conclusions The microRNA-196a2T/C polymorphism(rs1614913)is associated with an increased risk of lung cancer.The miRNA-196a2 functional polymorphism rs11614913 might be an effective genetic marker for lung cancer.
出处 《滨州医学院学报》 2016年第2期85-88,共4页 Journal of Binzhou Medical University
基金 山东省高校科技计划项目(J13LE11)
关键词 肺癌 miRNA-196a2 单核苷酸多态性 高分辨率溶解曲线 Lung cancer miRNA-196a2 SNP HRM
  • 相关文献

参考文献21

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013 [J].CA Cancer J C1in,2013,63(1) : 11-30.
  • 2Hongbin J,Danan L,Liang C,et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies [J].ancer Cell, 2006,9 (6) : 485-495.
  • 3Mahoney C, Choudhury B H, Edkins S, et al. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition[J]. British Journal of Cancer, 2009,100(2) : 370-375.
  • 4To M D,Wong C E, Karnezis A N, et al. Kras regulatory ele- ments and exon 4A determine mutation specificity in lung cancer [J]. Nature Genetics,2008, 40(10) :1240-1244.
  • 5Hatanaka H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007, 448 (7153) :561-566.
  • 6Paez JG, Janne PA,Lee JC,et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J].Science, 2004,304(5676) : 1497-1500.
  • 7Shaw AT, Yeap BY,Solomon BJ,et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis [J]. Lancet Oncology,2011,12(11) :1004-1012.
  • 8Rodrigo A, Bengt B, Ariane D, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer[J]. New England Journal of Medicine, 2004,350 (4) : 351-360.
  • 9Siegel R L, Fedewa S A, Miller K D, et al. Cancer statistics for Hispanics/Latinos, 2015[J]. Ca A Cancer Journal for Clinicians, 2015, 65(6):457-480.
  • 10Kim N. Regulation of microRNA biogenesis[J]. Nature Reviews Molecular Cell Biology, 2014,15 (8) : 605-610.

同被引文献8

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部